Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00408)
Name
Methazolamide
Synonyms    Click to Show/Hide the Synonyms of This API
methazolamide; 554-57-4; Neptazane; Methenamide; Neptazaneat; Naptazane; N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide; (Z)-methazolamide; UNII-W733B0S9SD; CHEBI:6822; L584601; UNII-DA43GW06P1; MLS000028532; CHEMBL288100; DA43GW06P1; W733B0S9SD; Acetamide, N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-; Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-; NCGC00016508-01; Metazolamide; CAS-554-57-4; SMR000058287; N-(3-Methyl-5-Sulfamoyl-1,3,4-Thiadiazol-2(3h)-Ylidene)acetamide; Metazolamide [DCIT]; Metazolamida; Methazolamidum; C5H8N4O3S2; N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide; Metazolamida [INN-Spanish]; Methazolamidum [INN-Latin]; HSDB 3269; SR-05000001844; EINECS 209-066-7; BRN 0232387; 2-Acetylimino-3-methyl-.delta.(4)-1,3,4-thiadiazoline-5-sulfonamide; 3-methyl-2-(2-oxo-1-azapropylidene)-1,3,4-thiadiazoline-5-sulfonamide; 5-Acetylimino-4-methyl-.delta.(2)-1,3,4-thiadiazoline-2-sulfonamide; N-(4-Methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)acetamide; N-(5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene)acetamide #; Acetamide, N-(4-methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)-; Neptazane (TN); Methazolamide,(S); Methazolamide [USP:INN:BAN:JAN]; Methazolamide, MZA; Prestwick_1007; Methazolamide (MZA); Methazolamide, (Z)-; Spectrum_001615; Opera_ID_717; CHEMBL19; Prestwick0_000802; Prestwick1_000802; Prestwick2_000802; Prestwick3_000802; Spectrum2_001543; Spectrum3_001914; Spectrum4_000190; Spectrum5_001006; 2-Acetylimino-3-methyl-delta(sup 4)-1,3,4-thiadiazoline-5-sulfonamide; 5-Acetylimino-4-methyl-delta(sup 2)-1,3,4-thiadiazoline-2-sulfonamide; DSSTox_CID_3281; N-(4-Methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide; cid_4100; DSSTox_RID_76956; DSSTox_GSID_23281; Oprea1_161738; SCHEMBL24686; SCHEMBL24687; BSPBio_000663; BSPBio_003508; KBioGR_000739; KBioSS_002095; 4-27-00-08221 (Beilstein Handbook Reference); MLS001146905; DivK1c_000582; SPECTRUM1503252; SPBio_001386; SPBio_002584; BPBio1_000731; GTPL6828; Methazolamide (JAN/USP/INN); VVP808; US10172837, Methazolamide; CHEMBL1335656; DTXSID1023281; SCHEMBL13825893; BDBM10881; CHEBI:94513; HMS501N04; KBio1_000582; KBio2_002095; KBio2_004663; KBio2_007231; KBio3_003013; VVP-808; Methazolamide, >=98% (HPLC); NINDS_000582; BDBM315269; HMS1570B05; HMS1922M19; HMS2093A05; HMS2097B05; HMS2234L03; HMS3259H05; HMS3372G12; HMS3652E21; HMS3714B05; HMS3747O09; Pharmakon1600-01503252; EBD27355; HY-B0553; Carbonic Anhydrase IX Inhibitor III; Tox21_110464; BDBM50013792; CCG-39321; MFCD00083416; NSC758426; SBB037875; ZINC12503151; AKOS015897587; AKOS024464790; AKOS026749792; N-(3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene)acetamide; ZINC100019188; ZINC253917094; CCG-266836; DB00703; KS-5328; MCULE-1665001985; NC00618; NSC-758426; SB17307; Acetamide, N-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)-; IDI1_000582; NCGC00016508-04; NCGC00016508-18; NCGC00018188-01; NCGC00018188-02; NCGC00018188-03; NCGC00018188-04; NCGC00018188-05; NCGC00018188-06; NCGC00018188-07; NCGC00022950-03; NCGC00022950-04; NCGC00178022-01; NCGC00178022-02; AC-32472; AK163546; AS-13272; ST081366; SBI-0051804.P002; AB0013250; DB-052736; AB00490015; SW197085-3; C07764; D00655; K-9905; AB00052336_04; 554M574; A830656; Methazolamide, VETRANAL(TM), analytical standard; L-584601; Q1149099; SR-05000001844-1; SR-05000001844-2; SR-05000001844-3; BRD-K13356952-001-15-2; BRD-K71053238-001-03-6; BRD-K71053238-001-04-4; Q27276292; (E)-N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene; N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)ethanamide; (NZ)-N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide; Methazolamide, United States Pharmacopeia (USP) Reference Standard; (E)-N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene)acetamide; N-[(2E)-3-Methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide; N-[(2Z)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide; 1164547-86-7
Clinical Status
Approved
Disease Indication Glaucoma ICD-11: 9C61 [1]
PubChem CID
4100
Formula
C5H8N4O3S2
Canonical SMILES
CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C
InChI
1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)
InChIKey
FLOSMHQXBMRNHR-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4100"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 236.3 Topological Polar Surface Area 139
XlogP 0.1 Complexity 419
Heavy Atom Count 14 Rotatable Bond Count 1
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 6
Full List of Drug Formulations (DFMs) Containing This API
          Methazolamide 25 mg tablet Click to Show/Hide the Full List of Formulation(s):          5 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline; Hypromellose 2910 (3 mpa.s)
                   Dosage Form Oral Tablet
                   Company Sandoz
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Calcium phosphate, dibasic, dihydrate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline
                   Dosage Form Oral Tablet
                   Company Effcon Laboratories
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Calcium phosphate, dibasic, dihydrate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline
                   Dosage Form Oral Tablet
                   Company Paddock Laboratories,
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
             Drug Formulation 4 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Dibasic calcium phosphate dihydrate; Croscarmellose sodium; Cellulose, microcrystalline; Colloidal silicon dioxide
                   Dosage Form Oral Tablet
                   Company Fera Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
             Drug Formulation 5 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl dibehenate; Dibasic calcium phosphate dihydrate; Povidone k30; Sodium starch glycolate type a potato; Starch, corn
                   Dosage Form Oral Tablet
                   Company ANI Pharmaceuticals
          Methazolamide 50 mg tablet Click to Show/Hide the Full List of Formulation(s):          5 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline; Hypromellose 2910 (3 mpa.s)
                   Dosage Form Oral Tablet
                   Company Physicians Total Care; Sandoz
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Calcium phosphate, dibasic, dihydrate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline
                   Dosage Form Oral Tablet
                   Company Effcon Laboratories
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Calcium phosphate, dibasic, dihydrate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline
                   Dosage Form Oral Tablet
                   Company Carilion Materials Management; Paddock Laboratories,
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
             Drug Formulation 4 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Dibasic calcium phosphate dihydrate; Croscarmellose sodium; Cellulose, microcrystalline; Colloidal silicon dioxide
                   Dosage Form Oral Tablet
                   Company Fera Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
             Drug Formulation 5 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl dibehenate; Dibasic calcium phosphate dihydrate; Povidone k30; Sodium starch glycolate type a potato; Starch, corn
                   Dosage Form Oral Tablet
                   Company ANI Pharmaceuticals
References
1 A repeated dose-response study of methazolamide in glaucoma. Arch Ophthalmol. 1978 Dec;96(12):2214-8.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.